Shares of Allergan PLC (NYSE:AGN) rose 1.9% during mid-day trading on Wednesday . The stock traded as high as $246.16 and last traded at $244.18, with a volume of 2,226,613 shares trading hands. The stock had previously closed at $239.70.

Several equities analysts recently commented on AGN shares. Mizuho reaffirmed a “neutral” rating and set a $232.00 price objective (down previously from $250.00) on shares of Allergan PLC in a research note on Tuesday, May 10th. Piper Jaffray Cos. reaffirmed a “hold” rating and set a $236.00 price objective on shares of Allergan PLC in a research note on Saturday, June 18th. Leerink Swann reaffirmed a “buy” rating and set a $340.00 price objective on shares of Allergan PLC in a research note on Tuesday, April 5th. Vetr cut shares of Allergan PLC from a “strong-buy” rating to a “buy” rating and set a $275.94 price objective for the company. in a research note on Thursday, June 2nd. Finally, Royal Bank Of Canada reaffirmed an “outperform” rating and set a $354.00 price objective on shares of Allergan PLC in a research note on Tuesday, April 5th. Six analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $306.06.

The company has a 50-day moving average of $237.80 and a 200 day moving average of $258.10. The company has a market capitalization of $96.50 billion and a price-to-earnings ratio of 21.83.

Allergan PLC (NYSE:AGN) last released its quarterly earnings results on Tuesday, May 10th. The company reported $3.04 earnings per share for the quarter, topping analysts’ consensus estimates of $3.03 by $0.01. The business had revenue of $3.80 billion for the quarter, compared to analysts’ expectations of $3.97 billion. The company’s revenue was up 48.1% on a year-over-year basis. Equities research analysts predict that Allergan PLC will post $14.20 earnings per share for the current fiscal year.

In related news, Director Nesli Basgoz sold 459 shares of the firm’s stock in a transaction dated Wednesday, May 11th. The stock was sold at an average price of $225.10, for a total transaction of $103,320.90. Following the completion of the transaction, the director now directly owns 5,242 shares in the company, valued at approximately $1,179,974.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Maria Teresa Hilado bought 661 shares of the stock in a transaction that occurred on Thursday, June 2nd. The shares were purchased at an average price of $241.57 per share, with a total value of $159,677.77. Following the completion of the acquisition, the chief financial officer now directly owns 11,957 shares in the company, valued at $2,888,452.49. The disclosure for this purchase can be found here.

Other institutional investors have recently made changes to their positions in the company. Twin Capital Management Inc. boosted its position in shares of Allergan PLC by 0.6% in the fourth quarter. Twin Capital Management Inc. now owns 4,379 shares of the company’s stock worth $1,368,000 after buying an additional 26 shares during the period. Boston Family Office LLC boosted its position in shares of Allergan PLC by 1.0% in the fourth quarter. Boston Family Office LLC now owns 7,123 shares of the company’s stock worth $2,226,000 after buying an additional 70 shares during the period. Spectrum Management Group Inc. boosted its position in shares of Allergan PLC by 1.7% in the fourth quarter. Spectrum Management Group Inc. now owns 4,874 shares of the company’s stock worth $1,523,000 after buying an additional 80 shares during the period. Ameritas Investment Partners Inc. boosted its position in shares of Allergan PLC by 2.1% in the fourth quarter. Ameritas Investment Partners Inc. now owns 7,544 shares of the company’s stock worth $2,357,000 after buying an additional 158 shares during the period. Finally, Wetherby Asset Management Inc. boosted its position in shares of Allergan PLC by 0.7% in the fourth quarter. Wetherby Asset Management Inc. now owns 26,866 shares of the company’s stock worth $8,395,000 after buying an additional 179 shares during the period.

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.